Resource • Article
Biorasi Starts First COVID-19 Clinical Trial in May 2020
Aventura, FL (May 6, 2020) – Biorasi, a leading global full-service contract research organization (CRO), is proud to announce the initiation of the company’s first COVID-19 clinical trial in May 2020. The U.S.-based trial will focus on the treatment for lung injuries caused by the COVID-19 virus.
“In the midst of this global healthcare crisis, we are honored to be included in the fight against this pervasive virus,” said Chris O’Brien, CEO of Biorasi. “With recruitment for this study set to be completed by the end of Q3 2020, we are excited to bring a much-needed measure of hope to patients affected by the severe complications associated with COVID-19.”
Apart from patient treatment measures confined to the facility ICU, operational aspects of the trial will be highly virtualized. These will include virtual site selection visits (SSVs), site initiation visits (SIVs), and remote/centralized monitoring.
“At Biorasi, we know that a robust decentralization strategy, ranging from home care visits to completely virtual trials, is a smart solution for conducting clinical trials in the wake of COVID-19 and beyond,” noted O’Brien. “We look forward to supporting trial stake holders and patients by leveraging our experience in innovative clinical program management as well as digital technology solutions.”
Biorasi is a customer-focused, full-service, contract research organization (CRO) that optimizes the design and delivery of clinical trials for its sponsors, powered by our proprietary TALOS™ project management system. Pharmaceutical companies around the globe rely on Biorasi to consistently deliver success in clinical trial programs for rare and orphan disease and other hard to recruit patient populations such as precision medicine, as well as successful clinical trial rescue. Biorasi’s expertise includes a wide range of molecule types, therapeutic areas, and regulatory pathways. Biorasi is a leader in neurology, nephrology, dermatology, oncology, and the emerging digital therapeutics market.
Established in 2002, Biorasi is headquartered in Aventura, FL, with office-based teams around the globe. From its regional presences, Biorasi is able to directly support studies in the Americas, Europe, and APAC. The company has received the coveted CRO Leadership Award from Life Science Leader magazine and has been placed on the INC 500 list of fastest-growing companies in America.
To learn more about Biorasi’s mission and vision, including our full spectrum of decentralized clinical trials, explore our solutions on our website or contact us at firstname.lastname@example.org or (786) 388-0700.